Krishgen Biosystems has released two latest ELISA assay kits for SARS-CoV-2 research and vaccine development and is validating a serology-based antibody screening ELISA kit with Wockhardt Hospitals, Mumbai

National Biomedical Resources Indigenization Consortium NBRIC is delighted to announce that NBRIC member, Mumbai-based biotech co Krishgen Biosystems has released two latest Assays for SARS-CoV-2 (Covid-19) Research – GENLISA surrogate Virus Neutralization Test ELISA and the GENLISA Inhibitor Screening ELISA. 

Krishgen Biosystems, is a bio-supplier company focused on offering solutions for immunoassays, cell cultures and toxicology to researchers. They have released 2 new assays called GENLISA surrogate Virus Neutralization Test (sVNT) ELISA and GENLISA Inhibitor Screening ELISA kits for vaccine developers and new drug manufacturers working on SARS-CoV-2 (Covid-19).  

The GENLISA sVNT ELISA is based on the principal of virus neutralization test. The second assay GENLISA Inhibitor Screening ELISA detects presence of potential inhibitors in the samples to compete with human ACE2 protein in combining with the SARS Cov2 S protein.

Krishgen has also signed a MOU with Wockhardt Hospitals Mumbai, Department of Stem Cells to test their Anti-SARS-CoV-2 IgG spike protein ELISA and another Nucleoprotein Antibody IgG ELISA as per protocol.

Constituted by Department of Biotechnology, Government of India and hosted, convened by C-CAMP, NBRIC is a collaborative Public Private Partnership to drive indigenous innovation focused on developing reagents, diagnostics, vaccines and therapeutics for COVID19 and beyond.

About Krishgen: